A Phase I/IIa, dose escalation and dose expansion, first-in-human, open-label, multicenter, single-arm study evaluating the safety, tolerability, dosimetry, and early efficacy of [177Lu]Lu- SN201 in participants with progressive or treatment-refractory locally advanced unresectable, metastatic or recurrent solid tumors.